MedTrace Logo

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

NCT07467772 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-22

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is:

-Elacestrant (a type of selective estrogen receptor degrader)

Conditions

  • Uterine Sarcoma
  • Uterine Leiomyosarcoma
  • Endometrial Stromal Sarcoma
  • ESS
  • Perivascular Epithelioid Cell Tumors
  • Uterine Adenosarcoma
  • Uterine PEComa
  • Estrogen Receptor Positive Tumor
  • uLMS

Interventions

DRUG

Elacestrant

Selective estrogen receptor degrader, tablet taken orally per protocol.

Sponsors & Collaborators

Principal Investigators

  • Suzanne George, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-25
Primary Completion
2027-07-31
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07467772 on ClinicalTrials.gov